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Abstract
Objective: Roux-en-Y gastric bypass (RYGB) is an effective way to induce sustainable 
weight loss and can be complicated by postprandial hyperinsulinaemic hypoglycaemia 
(PHH). To study the prevalence and the mechanisms behind the occurrence of 
hypoglycaemia after a mixed meal tolerance test (MMTT) in patients with primary RYGB.
Design: This is a cross-sectional study of patients 4 years after primary RYGB.
Methods: From a total population of 550 patients, a random sample of 44 patients 
completed the total test procedures. A standardized mixed meal was used as stimulus. 
Venous blood samples were collected at baseline, every 10 min during the first half 
hour and every 30 min until 210 min after the start. Symptoms were assessed by 
questionnaires. Hypoglycaemia is defined as a blood glucose level below 3.3 mmol/L.
Results: The prevalence of postprandial hypoglycaemia was 48% and was asymptomatic 
in all patients. Development of hypoglycaemia was more frequent in patients with lower 
weight at surgery (P = 0.045), with higher weight loss after surgery (P = 0.011), and with 
higher insulin sensitivity calculated by the homeostasis model assessment indexes 
(HOMA2-IR, P = 0.014) and enhanced beta cell function (insulinogenic index at 20 min, 
P = 0.001).
Conclusion: In a randomly selected population 4 years after primary RYGB surgery, 48% of 
patients developed a hypoglycaemic event during an MMTT without symptoms, suggesting 
the presence of hypoglycaemia unawareness in these patients. The findings in this study 
suggest that the pathophysiology of PHH is multifactorial.
Introduction
The laparoscopic Roux-en-Y gastric bypass (RYGB) is often 
used to achieve sustained weight loss, resolve comorbidity 
and improve survival in patients with obesity (1).
It is an effective procedure, but unfortunately, it 
can be accompanied by long-term complications such 
as postprandial hyperinsulinaemic hypoglycaemia 
(PHH) (2, 3).
PHH typically occurs 1–3 h after a meal and can lead 
to autonomic and neuroglycopenic symptoms such as 
sweating, palpitations, hunger and drowsiness, which 
may even result in coma (4, 5, 6). Studies have observed 
prevalence rates after primary gastric bypass surgery of 
12% when assessed by means of questionnaires and up 
to 75% when assessed by continuous glucose monitoring 
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systems (CGMSs) (7). Glucagon-like peptide-1 (GLP-1) is 
assumed to play a pivotal role in the pathophysiology of 
PHH, most convincingly because the GLP-1 antagonist 
exendin (9-39) prevents postprandial hyperinsulinaemia 
and the subsequent hypoglycaemia in people with severe 
symptoms of late dumping (8, 9). Other gut hormones 
may also play a role after gastric bypass surgery such 
as peptide tyrosine tyrosine (PYY) in reducing appetite 
and suppressing pancreatic secretion and the vasoactive 
intestinal peptide (VIP) as a local neuromodulator released 
by intrinsic enteric neurons and responsible for the 
induction of intestinal gluconeogenesis through a VPAC1 
receptor‐dependent mechanism in enterocytes (10, 11, 12). 
The role of these hormones in PHH is not clear (12, 13).
Although these studies have provided more insight 
into PHH, several (methodological) shortcomings should 
be mentioned. First of all, the questionnaires and symptom 
scales that were used for the assessment of the prevalence 
of PHH have not been validated. Further, these subjective 
methods do not take hypoglycaemic unawareness into 
account, a phenomenon that is described in patients with 
diabetes who have frequent episodes of hypoglycaemia 
(14). Diagnostic tools like CGMS have the advantage of 
monitoring glucose concentrations during daily activities, 
but the accuracy of CGMS in the hypoglycaemic range 
is poor (15, 16). Also, this method cannot be utilized to 
investigate the pathophysiology of PHH. Dynamic (or 
provocative) testing, however, can provide more insight 
into the pathophysiology, for instance, by providing 
a standardized stimulus or meal in a laboratory while 
performing extensive hormone analyses. Older studies have 
used the oral glucose challenge as standardized stimulus, 
but nowadays this is considered not physiological accurate; 
therefore, the mixed meal tolerance test (MMTT) is preferred 
(17). Smaller studies including up to ±20 patients using the 
MMTT after gastric bypass have been performed comparing 
patients with spontaneous severe hypoglycaemic symptoms 
to those without them (18, 19). These extremes of the 
spectrum of PHH have been informative, but do not allow a 
proper evaluation of the real prevalence of PHH and its main 
driving mechanisms in those with milder or no symptoms. 
For this purpose, a random selection of sufficient numbers 
of patients is necessary.
Therefore, we investigated the prevalence of PHH 
by venous sampling and by questionnaires during an 
MMTT in a random sample of patients with primary 
RYGB. Furthermore, to gain insight in the mechanisms 
provoking hypoglycaemia, we performed gut hormone 
analyses and assessed the beta-cell function and insulin 
resistance with several indices.
Patients and methods
Study population
Details on the study design were described previously 
(20). In brief, non-diabetic patients aged 18–75 years who 
underwent primary RYGB between 2008 and 2011 in our 
centre were eligible to participate in the study. A power 
analysis was performed and it revealed that a sample size 
of 50 patients was able to show a prevalence of at least 11% 
(based on an earlier study with self-reported symptoms of 
late dumping). From the entire cohort (n = 550), a random 
sample of 140 patients was drawn. All patients underwent 
an antecolic–antegastric Roux-en-Y reconstruction with 
a gastric pouch sized 30–60 mL, a biliopancreatic limb 
length of 80 cm and an alimentary limb length of 150 cm 
(21). In total, 51 patients agreed to participate, but due 
to exclusion and withdrawal of consent, only 44 patients 
were analysed. The selection process, as well as reasons for 
exclusion, is shown in Fig. 1. One patient was registered 
as having a primary gastric bypass, but during the test, 
we found out she had gastric banding before, and so 
she was excluded from the analysis. The study protocol 
was approved by the Regionale Toetsingscommissie 
Patiëntgebonden Onderzoek Leeuwarden (local Medical 
Ethical Review Board) and all patients provided written 
informed consent. This study was conducted between 
February 2014 and March 2015.
Study protocol
All scheduled patients underwent the MMTT in 
the morning after an overnight fast of at least 8 h. 
Anthropometric measures were obtained before the test 
meal and throughout the test. Via a peripheral intravenous 
cannula, blood samples were obtained before the meal 
(t = 0) and at 10, 20 and 30 min followed by every half 
hour until 210 min after the meal. Before the beginning of 
the test and at every 30 min until 210 min after the meal, 
patients filled in symptom-related questionnaires.
The mixed meal consisted of a 200 mL liquid nutrition 
supplement (Abbott Ensure S Plus) containing 300 kcal, 
12.5 g protein, 40.4 g carbohydrate (of which 13.8 g is 
sugars), 9.84 g fat and 154.9 g water. The patients were 
asked to finish the meal within 10 min.
Blood analyses
Venous blood for glucose and insulin analysis was 
collected in lithium–heparin tubes with a gel separator. 
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For the measurement of Peptide YY (PYY), VIP, active 
GLP-1 and inactive GLP-1, blood was collected in 
pre-cooled tubes containing 15% aprotonin; to this, 
50 μL dipeptidyl peptidase 4 (DPP-4) inhibitor (Merck 
Millipore DPP4-010) was added by injection through 
the cap directly prior to blood withdrawal without 
influencing the integrity of the pre-existing vacuum in 
the tube (22). All samples were centrifuged at 4°C and 
analysed immediately (glucose and insulin) or stored at 
–80°C until analysed (GLP-1, VIP and PYY).
The glucose (hexokinase reaction) and insulin 
analyses (sandwich principle assay) were performed on 
a Roche Diagnostics Cobas analytical unit (glucose with 
701 module; insulin with 801 module).
The concentrations of the active GLP-1, VIP, inactive 
GLP-1 and PYY were determined using commercial ELISA 
kits on a two-plate ELISA processing system (DS2, DYNEX 
Technologies, Chantilly, VA, USA), as per the manufacturer’s 
instructions. The following commercial ELISA kits were 
used for the active form and inactive form of GLP-1: IBL 
International, Hamburg, Germany, code JP27784 and code 
JP27788. For human VIP: RayBiotech, Norcross, GA, USA, 
cat. # EIA-VIP. For human PYY: Millipore Corporation, cat. 
# EZHPYYT66K. For the active and inactive forms of GLP-1 
and VIP, low- and high-level internal quality controls (QCs) 
were prepared by selecting and pooling plasma containing 
15% aprotonin and DPP-4 inhibitor (Merck Millipore 
DPP4-010). Low and high QCs for human PYY were 
provided by the manufacturer. The inter-assay variations 
of the low-level internal QC and the high-level internal 
QC were 57.0 and 43.7% for active GLP-1; 7.4 and 15.7% 
for inactive GLP-1; 62.0 and 54.1% for human VIP and 
12.1 and 17.2% for human PYY, respectively. Considering 
these variations, only within-subject changes from 
baseline were used for analysis. The maximum storage was 
30 months. We did not analyse stability of the incretins, 
but we assume that with the precautions made (immediate 
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Symptoms were assessed during the MMTT with the 
dumping severity score (DSS) developed by Arts et al. This 
questionnaire is based on symptom pattern descriptions 
in the literature, using a four-point Likert scale (23). 
The patient is asked to grade the intensity (0 = absent; 
1 = mild; 2 = moderate and 3 = severe, interfering with 
daily activities) of eight early-dumping symptoms 
(within 1 h after food ingestion) and six symptoms 
associated/attributed with/to hypoglycaemia (more 
than 1 h after food ingestion). These six hypoglycaemic 
symptoms are either adrenergic (sweating, palpitations, 
hunger, tremor) or neuroglycopenic (irritability, 
drowsiness) (23).
If patients rated three or more symptoms at an 
intensity 2 or 3 (i.e. moderate or severe, interfering with 
daily activities) on the DSS of which at least one was a 
neuroglycopenic symptom, this was considered a clinically 
relevant sign of postprandial hypoglycaemia based on 
previous research (21). To assess the psychological impact 
of these complaints, we also asked if this provoked 
anxiety or insecurity. In addition to the DSS, all patients 
were asked to report any other accompanying symptoms.
During the test, all patients were also observed for 
symptoms of hypoglycaemia by the researchers with open 
and specific questions and observation of physical evidence 
of symptoms (sweating, trembling, drowsiness, etc.).
Definition of PHH
Patients were divided into two groups, a group with 
hypoglycaemia defined as a postprandial glucose 
concentration <3.3 mmol/L and a group without 
hypoglycaemia defined by a postprandial glucose 
concentration ≥3.3 mmol/L in accordance with the 
guidelines (17). Symptomatic PHH was defined as 
hypoglycaemia in combination with a positive score on the 
DSS. Asymptomatic PHH was defined as hypoglycaemia 
without or with mild symptoms of neuroglycopenic or 
adrenergic symptoms.
Calculations of beta-cell function and 
insulin sensitivity
In the fasting state
The HOMA-IR was calculated as the product of fasting 
baseline levels of circulating glucose and insulin divided 
by 22.5 (Basalgluc × Basalins/22.5) (24). The quantitative 
insulin sensitivity check index (QUICKI) was calculated 
by 1/(log(fasting insulin in ng/ml) + (log(fasting glucose 
in mg/dL) (25). The HOMA-β was calculated with 
fasting glucose and insulin concentrations using the 
HOMA2 calculator available at http://www.dtu.ox.ac.uk/
homacalculator/index.php.
In the postprandial state
Insulin resistance was calculated using the formula of 
the product of the area under the curves (AUCs) of the 
circulating glucose and insulin responses (AUCgluc × AUCins) 
as used during an OGTT (26).
Insulin sensitivity calculations were based upon 
the Matsuda Index (MISI) and was calculated as 10,000/
(square root of (fasting glucose × fasting insulin) × (mean 
glucose × mean insulin)) (27). The insulin secretion index 
(ISI) was calculated by dividing the total AUC for insulin 
at 60 min by the total AUC for glucose at 60 min.
The β-cell sensitivity was calculated by three different 
methods. First, by the ratio of the AUCss of the circulating 
insulin and glucose responses (AUCins/AUCgluc) (7, 9). 
Secondly, by the liquid mixed meal tolerance disposition 
index (LMTT-DI), which was calculated according 
the following formula; MISI × ISI (10). Lastly, by the 
insulinogenic index calculated as the change in the 
insulin concentration at 10, 20 or 30 min versus baseline 
divided by the change in glucose in the corresponding 
time period.
Statistical analysis
Data are presented as mean (± standard deviation), median 
(interquartile ranges (IQR)), frequencies or percentages, 
where appropriate.
In order to study the representativeness of the 
included study population, it was compared with the 
entire population and the random selection for age, sex, 
preoperative weight and preoperative comorbidities with 
the independent Student’s t tests and Fisher’s exact tests.
Differences between the group with hypoglycaemia 
and the group without hypoglycaemia were assessed with 
t tests (for continuous variables) or chi-square tests (for 
categorical variables). An alpha level of 0.05 was used 
for determining statistical significance. For graphical 
representations, the mean with the standard error of the 
mean are shown. All statistical analyses were performed 
using the Statistical Package for the Social Sciences (SPSS, 
Inc.), version 23.
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Data of 44 patients were available for analysis; 32 women 
and 12 men with a median age of 47 years (39–56); all 
demographic characteristics are presented in Table 1. The 
study population was representative of the entire surgical 
cohort (n = 550) in terms of age, sex, comorbidities before 
surgery, preoperative weight and postoperative weight at 
the time of the study (Table 2).
Patients who developed hypoglycaemia during the 
MMTT were more often female, had a shorter follow-up 
after surgery, had less often a history of type 2 diabetes, 
had a lower BMI and weight at the MMTT and had lost 
more (excess) weight after gastric bypass surgery (Table 1).
Glucose and insulin
Hypoglycaemia was present in 21 patients (48%) 
occurring between 30 and 150 min, but mostly between 
60 and 120 min (Fig. 2). One patient started the MMTT 
with a fasting glucose concentration of 2.9 mmol/L; this 
increased to 9.5 mmol/L at 20 min after the meal and after 
60 min, the patient had a hypoglycaemia with a nadir 
glucose concentration of 1.7 mmol/L. Thirteen patients 
(30%) developed hypoglycaemia with a nadir glucose 
concentration below 2.8 mmol/L. Patients who developed 
a hypoglycaemic episode had significantly lower glucose 
values at baseline and on all time points after ingestion 
of the meal except for 10, 180 and 210 min. Insulin 
concentrations were significantly higher at 10 and 30 min 
and significantly lower in the group with hypoglycaemia 
at baseline and in the late postprandial phase from 90 to 
210 min.
Hypoglycaemia-related symptoms
No differences in moderate or severe hypoglycaemic 
symptoms were seen between the group with 
hypoglycaemia versus the group without hypoglycaemia 
(Table 3).
In accordance with this, no symptoms of 
neuroglycopenia or adrenergic stimulation were observed 
by the investigators.
Insulin sensitivity and beta-cell function
All indices of insulin resistance showed that insulin 
sensitivity was significantly higher in the group 
with hypoglycaemia compared to the group without 
hypoglycaemia (Table 4).
In contrast, the HOMA2-β was not different between 
the groups; the estimates of the postprandial beta-
cell function showed an increased insulin secretion as 
calculated by the LMTT-DI and the insulinogenic index in 
the group with hypoglycaemia (Table 4).
Table 1 Comparison of patient characteristics between patients with and without hypoglycaemia.
Patients without hypoglycaemia (n = 23) Patients with hypoglycaemia (n = 21) P value
Age (years) 48 (42–56) 42 (39–56) 0.449
Female (%) 14 (61) 18 (86) 0.094
Time between surgery and study (months) 54 (44–58) 43 (38–53) 0.010
Weight and weight loss
 Weight at surgery (kg) 143 (128–157) 130 (120–147) 0.045
 BMI at surgery 45 (43–52) 45 (41–48) 0.287
 Weight at MMTT (kg) 99 (88–118) 85 (79–94) 0.001
 BMI at MMTT 32 (30–39) 29 (26–32) 0.014
 EWL at MMTT (%) 62 (48–76) 78 (64–92) 0.011
 TWL at MMTT (%) 28 (22–34) 33 (27–41) 0.036
Comorbidities preoperative
 Type 2 diabetes 13 (57) 1 (5) 0.000
 Hypertension 15 (61) 6 (29) 0.040
 Dyslipidaemiaa 6 (26) 3 (14) 0.462
Comorbidities postoperative
 Type 2 diabetesb 0 0
 Hypertension 6 (26) 4 (19) 0.902
 Dyslipidaemia 3 (13) 1 (5) 0.609
Data are median and interquartile ranges (IQR), or numbers and frequencies (percentages). Bold indicates statistical significance.
aDefined as patients using lipid-lowering medication. bExclusion criteria. 
EWL, excess weight loss; MMTT, mixed meal tolerance test; TWL, total weight loss.
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The concentrations of PYY, total GLP-1 and VIP measured 
as a percentage of change were not different between both 
groups (Fig. 3).
Discussion
In a random population 4 years after primary gastric bypass 
surgery, 48% of the patients developed a hypoglycaemic 
event (<3.3 mmol/L) without concurrent symptoms after 
a test meal. Patients who developed hypoglycaemia after 
a test meal were more often female and had lost more 
weight after their operation. In addition, they showed a 
higher insulin sensitivity (lower HOMA-IR and no prior 
history of type 2 diabetes) and an enhanced beta-cell 
function in the postprandial phase.
This is the first study consisting of a randomly 
selected, sufficiently large number of patients with a 
mid-term follow-up after primary gastric bypass surgery 
investigated with a dynamic test of sufficient duration. 
Previous studies have shown that the prevalence of PHH 
assessed with an oral glucose tolerance test varied between 
10.4 and 80% depending on the glucose load (75 or 100 g) 
and cut-off value (2.8 or 3.3 mmol/L) and selection of the 
study population (28, 29, 30, 31, 32).
The study by Raverdy et  al. on the prevalence of 
PHH contains data 60  months after RYGB and found a 
prevalence of 7.9% of PHH (33). However, they used an 
OGTT and measured only at 30 and 120 min after oral 
ingestion with a definition of PHH as having a glucose 
value lower than 2.8 mmol/L. We chose the MMTT as 
a provocation test as the composition of this liquid 
meal with a combination of fat, protein and 40 g of 
carbohydrate (of which 14 g is sugar) resembles a more 
normal food intake. To study the prevalence of PHH in a 
daily life setting, the MMTT is therefore a better test than 
the OGTT (17).
The first intriguing observation of our study is 
the high prevalence of PHH in combination with 
a total lack of related symptoms as reported by 
patients and as observed by the researchers. This 
phenomenon is known as hypoglycaemia unawareness 
or hypoglycaemia-associated autonomic failure (HAAF). 
Table 2 Comparison between the sample and entire surgical cohort of patients who had undergone primary gastric bypass.
Sample (N = 44) Entire cohort (N = 506) P value
Age (years) 45.3 (38.1–53.2) 44.4 (37.5–51.5) 0.859
Female (%) 32 (72.7) 403 (79.6) 0.332
Comorbidities preoperative
 Type 2 diabetes 13 (29.5) 112 (22.1) 0.265
 Hypertension 19 (43.2) 195 (38.5) 0.629
 Dyslipidaemia 9 (20.5) 84 (16.6) 0.535
Weight and weight loss
 Weight at surgery (kg) 137 (125–150) 130 (116–146) 0.820
 BMI at surgery 45 (42–48) 44 (41–48) 0.097
 Last weight at outpatient clinic (kg) 95.0 (84.3–106.8) 93.1 (82.0–110.0) 0.336
 Last BMI at outpatient clinic 30 (26–33) 31 (27–35) 0.746
 EWL (%) 75 (61–92) 69 (53–88) 0.263
 TWL (%) 32 (28–39) 30 (23–37) 0.625
Data are median and interquartile ranges (IQR), or numbers and frequencies (percentages).
Figure 2
Glucose and insulin levels in patients with and 
without a hypoglycaemic event. Data are 
mean ± s.e.m. *P value <0.05, **P value <0.01,  
***P value <0.001. Black line: patients without 
hypoglycaemia (glucose >3.3 mmol/L). Grey line: 
patients with hypoglycaemia (glucose 
≤3.3 mmol/L).
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It is frequently observed in people with type 1 diabetes 
on intensive insulin treatment who experience recurrent 
hypoglycaemia, but it has also been suggested to occur 
during PHH in the bariatric population (14). Our results 
are in line with Abrahamsson et  al. who performed a 
stepwise hypoglycaemic clamp study in patients before 
and 23  weeks after gastric bypass surgery (34). They 
found that not only the hypoglycaemia symptom score, 
but also the levels of counter-regulatory hormone such 
as glucagon, cortisol and catecholamine as well as the 
sympathetic nerve responses were much lower after 
surgery compared to those before. One study investigated 
15 RYGB patients without known hypoglycaemia by 
means of the CGMS and found that the patients had 
glucose concentrations below 3.3 mmol/L 2.9% of the 
time and 1.5% of the time, these concentrations dropped 
below 2.8 mmol/L (35). The patients were unaware of 
their hypoglycaemia four out of five (80%) times. Thus, 
it is plausible that the high prevalence of hypoglycaemia 
as seen in our study translates in daily life as recurrent 
hypoglycaemia, leading to hypoglycaemia-induced 
autonomic failure and hypoglycaemia unawareness. This 
could also explain the discrepancy of the prevalence of 
PHH measured during dynamic tests and by means of 
questionnaires.
Not only after gastric bypass surgery, but also in 
patients who underwent a vertical banded gastroplasty 
with 30% weight loss, a decrease in counter-regulation 
to hypoglycaemia has been observed (36). This suggests 
that the development of hypoglycaemia unawareness 
cannot be attributed to a specific type of bariatric 
surgery. The discrepancy between the asymptomatic 
low blood sugars in our study and the development of 
neuroglycopenia for which patients must be hospitalized 
in daily life is interesting and further research must 
clear this discrepancy of hypo-unawareness. The second 
main finding in the current study is the observation of 
differences in insulin sensitivity and insulin secretion 
between the groups with and without hypoglycaemia. 
The group with hypoglycaemia had in comparison with 
the group without hypoglycaemia a lower preoperative 
weight, more postoperative weight loss and were less likely 
to have a history of type 2 diabetes. All these are factors 
that are known to contribute to high insulin sensitivity. 
In our study, this was supported by lower fasting glucose 
and insulin concentrations and a lower HOMA2-IR. 
Table 3 Number of patients with (moderate and severe) symptoms in patients with (+) and without (−) hypoglycaemia.
Minutes after meal Sweating Palpitations Hunger Tremor Drowsiness Irritability
Hypoglycaemia − + − + − + − + − + − +
23 21 23 21 23 21 23 21 23 21 23 21
−15 0 1 (5) 0 1 (5) 4 (17) 1 (5) 2 (9) 2 (10) 1 (4) 1 (5) 1 (4) 1 (5)
60–90 0 0 0 0 1 (4) 2 (10) 0 0 2 (9) 4 (19) 0 0
90–120 0 0 0 0 1 (4) 2 (10) 0 0 2 (9) 2 (10) 0 0
120–150 1 (4) 0 0 0 1 (4) 3 (14) 0 0 3 (13) 2 (10) 0 0
150–180 1 (4) 0 0 0 5 (22) 7 (33) 0 1 (5) 2 (9) 0 0 1 (5)
180–210 1 (4) 0 0 0 7 (30) 10 (48) 0 0 1 (4) 1 (5) 0 1 (5)
Data are numbers and frequencies (percentages). No significances were observed between both groups.
Table 4 Differences in beta-cell function and insulin resistance.
No hypoglycaemia Hypoglycaemia P value
Insulin sensitivity
 HOMA2-IR 1.36 (0.68–1.70) 0.72 (0.50–1.01) 0.014
 Quicki-index 0.147 (0.140–0.164) 0.164 (0.157–0.179) 0.011
 MISI 4.3 (3.0–7.8) 7.8 (4.7–12.0) 0.014
 ISI 9.9 (7.7–14.1) 21.6 (11.3–24.2) 0.001
Beta cell function
 HOMA2-β 121 (77–158) 116 (99–137) 0.685
 LMTT-DI 36.9 (24.9–48.0) 95.8 (68.5–147.1) 0.000
 Insulinogenic index
  0–10 min 21.0 (10.8–43.4) 41.4 (23.1–62.9) 0.012
  0–20 min 19.7 (12.8–29.0) 43 (25.3–64.1) 0.001
  0–30 min 19.1 (14.0–34.7) 44.6 (26.6–66.5) 0.600
ISI, insulin secretion index; LMTT-DI, liquid mixed meal tolerance disposition index; MISI, Matsuda Index. Bold indicates statistical significance.
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Also contributing is the increased insulin secretion in 
the first half hour of the test and the disposition index, 
which was indicative of an enhanced postprandial beta-
cell function. Finally, the patients with a hypoglycaemic 
event returned to lower insulin levels at later time points. 
This could reflect higher insulin sensitivity. Our findings 
of higher insulin sensitivity and increased insulin 
secretion in patients with hypoglycaemia are in line 
with the prior studies (14, 28). One of these studies was 
by Guarino et  al. They performed an OGTT in patients 
who were all diabetic preoperatively, but the majority 
(74%) were at the time of testing postoperatively in 
remission (28). Also, Vaurs et al. found that the patients 
after RYGB with hypoglycaemia and during the OGTT 
had an increased insulin secretion rate in the first 
15 min. Just as in the current study, these patients had 
lost more weight postoperatively and were less frequently 
diagnosed with diabetes before surgery. However, they 
did not observe a difference in insulin sensitivity between 
patients with and without hypoglycaemia (14). This 
discrepancy with the current study could be explained 
by the difference in the definition of hypoglycaemia, 
which was a glucose concentration <2.8 mmol/L in 
Vaurs et  al. and <3.3 mmol/L in ours. However, it could 
also be caused by the difference in inclusion criteria, 
as they specifically included patients who experienced 
hypoglycaemic symptoms during daily life, while, in our 
current study, a random sample was drawn and none of 
the patients with hypoglycaemia during the MMTT had 
clinically relevant symptoms. A more rapid glucose peak 
and a higher GLP-1 response were found in patients with 
post-gastric bypass hypoglycaemia, suggesting a role for 
GLP-1 in the pathophysiology (28, 37). Blocking the 
GLP-1-receptor by the GLP-1-receptor antagonist exendin 
(9-39) abolishes the occurrence of hypoglycaemia during 
an MMTT, providing further evidence for a role of GLP-1 
in the pathogenesis of PHH (38). Interestingly, we did not 
find differences in the GLP-1, PYY and VIP concentrations 
between the group with hypoglycaemia versus the group 
without hypoglycaemia. Vaurs et al. also did not observe 
differences in GLP-1 (14). Difference in the stimulus, 
glucose versus a mixed meal, and the selection of patients 
could be the explanation for this discrepancy. Moreover, 
the lower glucose concentration, in the group with 
hypoglycaemia in our study, was already present in the 
fasting state, which suggests that the postprandial GLP-1 
hypersecretion is not the only mechanism contributing 
to PHH. This may be a consequence of a higher glucose 
sensitivity, but differences in hepatic glucose production 
by changes in glucagon concentrations or by changes in 
autonomic innervation have to be also considered. These 
mechanisms need to be studied further in detail.
The strength of our study is the random selection of 
patients with the cohort being comparable to the entire 
surgical cohort in terms of age, sex, comorbidities before 
surgery, preoperative weight and postoperative weight at 
the time of the study. Furthermore, we used an MMTT, 
which is more close to normal food intake compared to 
an OGTT.
Some limitations of the study must be mentioned. 
First, for various reasons, most unrelated to dumping, 
only 44 patients of the 51 patients in the random sample 
were tested, However, because most of these exclusions 
were due to problematic blood withdrawal, the risk of bias 
Figure 3
Changes in gut hormones from baseline 
(percentage change) of various gut hormones in 
patients with and without a hypoglycaemic event. 
Data are mean ± s.e.m. Black line: patients without 
hypoglycaemia (glucose >3.3 mmol/L). Grey line: 
patients with hypoglycaemia (glucose 
≤3.3 mmol/L).
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is low. The demographics of the tested patients were not 
different from the total group of operated patients, but 
there is still a possibility of selection bias.
Secondly, the test meal for an MMTT is not 
standardized, which is a general shortcoming of meal 
tests. Standardization should be recommended in order to 
compare studies in future research. Thirdly, patients were 
not tested before surgery and therefore other predictors 
beside the demographics cannot be extrapolated from our 
study. Pigeyre et  al. found in nondiabetic patients after 
RYGB that a normal glucose tolerance test and a lower 
HbA1c before surgery were predictors of the hypoglycaemia 
during a 75 g OGTT 12 months after surgery (39). Finally, 
for GLP-1, PYY and VIP, only relative changes compared 
to the baseline could be presented due to the (unexpected) 
large inter-assay variation. Another limitation is the fact that 
no validated questionnaire for early and late dumping is 
available. The best-known questionnaire is the Sigstad score, 
which was initially developed as a clinical score for early 
dumping to be administered by a doctor. Later, some have 
used a modified Sigstad score as a patient questionnaire and 
had employed this in post-gastrectomy patients in case of 
ulcer disease (32, 40). It is not widely used for post-gastric 
bypass hypoglycaemia. As indicated earlier, the Edinburgh 
hypoglycaemia questionnaire is also not validated for late 
dumping. A potentially more useful and newer patient 
questionnaire is the DSS, developed by Arts and colleagues 
(23). This questionnaire is used for the evaluation of 
treatment responses in patients with post-gastric bypass 
hypoglycaemia. Validated cut-off levels are not available.
From clinical practice, we know that PHH can be 
provoked by physical activity. Physical activity can influence 
insulin sensitivity. In this study, we did not ask patients 
about their physical activity in the days before the test. 
Also, patients were tested without performing any physical 
activity. Future research also must focus on this aspect.
Conclusion
In a randomly selected population mid-term after primary 
RYGB surgery, 48% of patients developed a hypoglycaemic 
event during an MMTT. No hypoglycaemic symptoms 
accompanied these events suggesting the presence 
of hypoglycaemia unawareness in these patients. The 
findings in this study suggest that the pathophysiology of 
PHH is multifactorial.
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